Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740665 | 0.88 | MAPT (0.72) | MAPTTSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL12288117 | 0.84 | MAPT (0.48) | MAPTVCAM1TSHRMEN1KMT2A | |
| SCHEMBL16003231 | 0.84 | MAPT (0.66) | MAPTTSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL5462361 | 0.82 | MAPT (0.64) | MAPTVCAM1TSHRPOLBHTT | |
| SCHEMBL3051207 | 0.82 | MAPT (0.52) | MAPTVCAM1TSHRMEN1KMT2A | |
| SCHEMBL6872660 | 0.82 | SMN1; SMN2 (0.48) | MAPTVCAM1TSHRMEN1KMT2A | |
| SCHEMBL3049451 | 0.81 | VCAM1 (0.40) | MAPTVCAM1LMNAPOLBHTT | |
| SCHEMBL5465567 | 0.81 | MAPT (0.51) | MAPTTSHRLMNAPOLBKDR | |
| SCHEMBL3033674 | 0.77 | MAPT (0.64) | MAPTTSHRMEN1KMT2ALMNA | |
| SCHEMBL11886403 | 0.76 | MAPT (1.00) | MAPTTSHRHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | MKI67, CDK4, PGF | MAPT 3142/4885VCAM1 640/4885TSHR 2127/4885 |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | MKI67, VEGFA, FLT1 | MAPT 1920/4885VCAM1 478/4885TSHR 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.